Does the media refer more to ROIV or COGT?

In the previous week, Cogent Biosciences had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Cogent Biosciences and 8 mentions for Roivant Sciences. Cogent Biosciences' average media sentiment score of 1.27 beat Roivant Sciences' score of 1.25 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is INCY or COGT more profitable?

Incyte has a net margin of 27.71% compared to Cogent Biosciences' net margin of 0.00%. Incyte's return on equity of 29.93% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Cogent Biosciences N/A -86.42% -48.97%

Does the media refer more to INCY or COGT?

In the previous week, Cogent Biosciences had 6 more articles in the media than Incyte. MarketBeat recorded 11 mentions for Cogent Biosciences and 5 mentions for Incyte. Incyte's average media sentiment score of 1.69 beat Cogent Biosciences' score of 1.27 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COGT or BNTX?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 11 articles in the media. Cogent Biosciences' average media sentiment score of 1.27 beat BioNTech's score of 0.58 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or COGT?

In the previous week, United Therapeutics had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 14 mentions for United Therapeutics and 11 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat United Therapeutics' score of 0.65 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COGT or MRNA?

In the previous week, Moderna had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for Moderna and 11 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat Moderna's score of 0.35 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Cogent Biosciences (COGT) Competitors

$37.31 -1.67 (-4.28%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$37.77 +0.46 (+1.23%)

As of 05:19 AM Eastern

Compare

COGT vs. ROIV, INCY, BNTX, UTHR, and MRNA

Should you buy Cogent Biosciences stock or one of its competitors? Cogent Biosciences's main competitors and comparable companies include Roivant Sciences (ROIV), Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cogent Biosciences compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,159.21	-$299.77M	-$0.53	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Roivant Sciences currently has a consensus target price of $35.14, indicating a potential downside of 3.15%. Cogent Biosciences has a consensus target price of $49.10, indicating a potential upside of 31.60%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Cogent Biosciences and 8 mentions for Roivant Sciences. Cogent Biosciences' average media sentiment score of 1.27 beat Roivant Sciences' score of 1.25 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Cogent Biosciences	N/A	-86.42%	-48.97%

64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

Roivant Sciences beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Incyte?

Incyte (NASDAQ:INCY) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Incyte has a net margin of 27.71% compared to Cogent Biosciences' net margin of 0.00%. Incyte's return on equity of 29.93% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Cogent Biosciences	N/A	-86.42%	-48.97%

97.0% of Incyte shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Incyte has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Incyte has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.75	$1.29B	$7.85	15.35
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Incyte presently has a consensus price target of $120.65, indicating a potential upside of 0.11%. Cogent Biosciences has a consensus price target of $49.10, indicating a potential upside of 31.60%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 6 more articles in the media than Incyte. MarketBeat recorded 11 mentions for Cogent Biosciences and 5 mentions for Incyte. Incyte's average media sentiment score of 1.69 beat Cogent Biosciences' score of 1.27 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats Cogent Biosciences on 12 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to BioNTech?

Cogent Biosciences (NASDAQ:COGT) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Cogent Biosciences and Cogent Biosciences both had 11 articles in the media. Cogent Biosciences' average media sentiment score of 1.27 beat BioNTech's score of 0.58 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cogent Biosciences presently has a consensus target price of $49.10, suggesting a potential upside of 31.60%. BioNTech has a consensus target price of $127.81, suggesting a potential upside of 38.75%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Cogent Biosciences has higher earnings, but lower revenue than BioNTech. Cogent Biosciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
BioNTech	$3.25B	7.18	-$1.29B	-$7.83	N/A

Cogent Biosciences has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-86.42%	-48.97%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

BioNTech beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

United Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

94.1% of United Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

United Therapeutics currently has a consensus price target of $646.00, suggesting a potential upside of 28.87%. Cogent Biosciences has a consensus price target of $49.10, suggesting a potential upside of 31.60%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, United Therapeutics had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 14 mentions for United Therapeutics and 11 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat United Therapeutics' score of 0.65 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Cogent Biosciences' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Cogent Biosciences	N/A	-86.42%	-48.97%

United Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

United Therapeutics beats Cogent Biosciences on 12 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to Moderna?

Cogent Biosciences (NASDAQ:COGT) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Moderna had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for Moderna and 11 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.27 beat Moderna's score of 0.35 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-86.42%	-48.97%
Moderna	-141.43%	-28.30%	-19.39%

Cogent Biosciences presently has a consensus target price of $49.10, suggesting a potential upside of 31.60%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 33.80%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

Cogent Biosciences has higher earnings, but lower revenue than Moderna. Cogent Biosciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Moderna	$1.94B	13.07	-$2.82B	-$7.99	N/A

Cogent Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cogent Biosciences and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.76B	$3.74B	$7.07B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-17.27	10.24	269.63	25.21
Price / Sales	N/A	1,287.04	600.52	101.12
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	9.72	17.84	13.17	6.24
Net Income	-$328.94M	-$13.30M	$3.45B	$347.70M
7 Day Performance	-11.98%	0.61%	0.74%	0.87%
1 Month Performance	-3.12%	0.48%	1.41%	0.90%
1 Year Performance	218.62%	54.57%	67.05%	20.13%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	2.3946 of 5 stars	$37.31 -4.3%	$49.10 +31.6%	+211.4%	$6.76B	N/A	N/A	80	Positive News Earnings Report Analyst Forecast
ROIV Roivant Sciences	1.6771 of 5 stars	$33.32 -1.7%	$33.59 +0.8%	+203.4%	$24.39B	$8.26M	N/A	860	Positive News Gap Down
INCY Incyte	3.5233 of 5 stars	$118.43 -0.9%	$119.60 +1.0%	+40.4%	$24.23B	$5.14B	15.09	2,844	Positive News Analyst Forecast
BNTX BioNTech	3.3277 of 5 stars	$92.25 +1.8%	$129.13 +40.0%	-18.3%	$22.91B	$3.25B	N/A	7,807
UTHR United Therapeutics	4.345 of 5 stars	$516.31 -0.3%	$648.33 +25.6%	+61.8%	$21.98B	$3.18B	19.06	1,400	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INCY, BNTX, UTHR, and MRNA

How does Cogent Biosciences compare to Roivant Sciences?

Summary

How does Cogent Biosciences compare to Incyte?

Summary

How does Cogent Biosciences compare to BioNTech?

Summary

How does Cogent Biosciences compare to United Therapeutics?

Summary

How does Cogent Biosciences compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INCY, BNTX, UTHR, and MRNA

How does Cogent Biosciences compare to Roivant Sciences?

Which has better earnings & valuation, ROIV or COGT?

Do analysts recommend ROIV or COGT?

Does the media refer more to ROIV or COGT?

Is ROIV or COGT more profitable?

Do insiders & institutionals have more ownership in ROIV or COGT?

Which has more risk and volatility, ROIV or COGT?

Summary

How does Cogent Biosciences compare to Incyte?

Is INCY or COGT more profitable?

Do institutionals and insiders have more ownership in INCY or COGT?

Which has more risk and volatility, INCY or COGT?

Which has better valuation and earnings, INCY or COGT?

Do analysts rate INCY or COGT?

Does the media refer more to INCY or COGT?

Summary

How does Cogent Biosciences compare to BioNTech?

Does the media favor COGT or BNTX?

Do insiders and institutionals have more ownership in COGT or BNTX?

Do analysts rate COGT or BNTX?

Which has more risk and volatility, COGT or BNTX?

Which has higher valuation and earnings, COGT or BNTX?

Is COGT or BNTX more profitable?

Summary

How does Cogent Biosciences compare to United Therapeutics?

Which has preferable earnings & valuation, UTHR or COGT?

Do institutionals & insiders hold more shares of UTHR or COGT?

Do analysts rate UTHR or COGT?

Does the media favor UTHR or COGT?

Is UTHR or COGT more profitable?

Which has more volatility and risk, UTHR or COGT?

Summary

How does Cogent Biosciences compare to Moderna?

Does the media favor COGT or MRNA?

Is COGT or MRNA more profitable?

Do analysts prefer COGT or MRNA?

Which has stronger valuation and earnings, COGT or MRNA?

Which has more volatility and risk, COGT or MRNA?

Do institutionals and insiders have more ownership in COGT or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools